Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.48 +0.09 (+2.14%)
As of: Aug 20, 2026 · 3:56 PM EDT

Apimeds Pharmaceuticals US (APUS) Net Equity Issued and Repurchased (2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Net Equity Issued and Repurchased came in at -$323319.0 in Q4 2025.

Apimeds Pharmaceuticals US (APUS) Net Equity Issued and Repurchased (2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 1 years of Net Equity Issued and Repurchased data on file, last reported at -$323319.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn -
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn 700,000.00
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn 84.80 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Apimeds Pharmaceuticals US 7.68 Mn 7.68 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -323,319.00
Dec 31, 2025 -323,319.00